Antibody drug conjugate targets are highly differentially expressed across the major types of ovarian cancer
EnOC and CCOC are usually FOLRα negative, while HGSOC, EnOC and CCOC frequently express B7-H4. TROP2 positivity is limited to HGSOC and EnOC. Careful consideration of histotype and ADC target expression levels is warranted when designing and analysing clinical studies of ADCs.
Authors
- Robert L. Hollis (ORCID: https://orcid.org/0000-0002-1390-3298)
- Charlie Gourley (ORCID: https://orcid.org/0000-0002-2377-7221)
- Rachel Nirsimloo (ORCID: https://orcid.org/0009-0007-5646-273X)
- C. Gourley
- Michael Churchman (ORCID: https://orcid.org/0000-0003-1958-7692)
- Ian Croy
- C. Simon Herrington (ORCID: https://orcid.org/0000-0001-9177-8165)
- Joanna M Porter
- Peter Sanderson (ORCID: https://orcid.org/0000-0001-8545-4260)
- Cheng Jin (ORCID: https://orcid.org/0009-0008-2847-7157)
- Marianne C. Stewart
- Elizabeth Brownsell
Institutions
- NHS Lothian (GB)
- Western General Hospital (GB)
- Edinburgh Cancer Research (GB)
- Edinburgh Royal Infirmary (GB)
Publication Details
- Journal
- European Journal of Cancer
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1016/j.ejca.2025.115522
- Citations
- 4
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 6.79
Funders
- Cancer Research UK
- Wellbeing of Women
- British Gynaecological Cancer Society